XML 20 R6.htm IDEA: XBRL DOCUMENT v3.19.1
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 9 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Cash flows from operating activities    
Net loss $ (12,600,007) $ (10,734,432)
Adjustments to reconcile net loss to cash used in operating activities    
Depreciation, amortization and accretion 1,974,213 1,975,448
Stock-based compensation expense 121,979 288,010
Issuance of restricted stock 600,863 158,585
Issuance of common stock to employee 11,690 0
Derivative (income) (65,468) (3,957,756)
Impairment of intangible assets 0 1,856,020
Other gain 0 (1,753,568)
Issuance of warrants 0 179,287
Warrant amendment 0 4,633
Changes in operating assets and liabilities:    
(Increase) in accounts receivable (797,576) (204,437)
(Increase) decrease in inventory (191,110) 428,401
(Increase) in prepaid expenses and other (364,831) (586,139)
(Decrease) increase in accounts payable and other (17,769) 967,641
Increase (decrease) in accrued liabilities 586,258 (571,121)
Increase in accrued compensation 250,912 558,451
Increase in interest payable - related party 134,795 0
(Decrease) in deferred rent (1,450) (5,005)
Net cash used in operating activities (10,357,501) (11,396,982)
Cash flows used in investing activities    
Deposits 2,888 0
Purchases of property and equipment (59,848) (74,707)
Contingent consideration payment (408,917) (7,385)
Purchase of assets (500,000) 0
Net cash used in investing activities (965,877) (82,092)
Cash flows from financing activities    
Issuance of preferred, common stock and warrants 15,180,000 24,740,015
Issuance costs related to preferred, common stock and warrants (1,479,963) (2,697,066)
Warrant exercises 258,512 640,380
Issuance of debt - related party 5,000,000 0
Net cash provided by financing activities 18,958,549 22,683,329
Net change in cash, cash equivalents and restricted cash 7,635,171 11,204,255
Cash, cash equivalents and restricted cash at beginning of period 7,112,527 877,542
Cash, cash equivalents and restricted cash at end of period 14,747,698 12,081,797
Fair value of warrants issued to investors and underwriters 1,888,652 0
Issuance of preferred stock related to purchase of asset 519,600 0
Contingent consideration (see Note 6) 8,833,219 0
Contingent consideration included in accounts payable 29,348 11,283
Warrants issued to investors and underwriters 0 4,117,997
Earn-out payment to Nuelle Shareholders in common stock 0 250,000
Warrant exercise of derivative warrants $ 0 $ 40,096